Truist assumed coverage of Wave Life Sciences (WVE) with a Buy rating and price target of $15, down from $50. The firm says the reduced price target reflects higher risk following the WVE-007 INHBE data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: